IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma ...Middle East

SHANGHAI and NANJING, China and PLEASANTON, Calif., Nov. 27, 2025 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for...

Hence then, the article about iaso bio announces bla approval of fucaso equecabtagene autoleucel by the hong kong department of health for the treatment of relapsed or refractory multiple myeloma was published today ( Thursday 27/11/2025 - 08:39 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma )

Also on site :

• Teenagers wreak havoc in Clapham during Easter holiday ‘link up’
• Spain’s FA condemns Islamophobic chants during game with Egypt
• Politics latest: Starmer to deliver cost of living update after latest Trump tirade over Iran war